Mecamylamine Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 2.5 mg, 5 mg,10 mg
Reference Brands: Vecamyl (USA/EU)
Category:
Neurology
Mecamylamine Hydrochloride is available in Tablets
and strengths such as 2.5 mg, 5 mg,10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Mecamylamine Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Mecamylamine Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Mecamylamine, marketed under brand names such as Inversine and Vecamyl, is a non-selective, non-competitive antagonist of nicotinic acetylcholine receptors (nAChRs). Originally introduced in the 1950s as an orally active antihypertensive agent, it functions as a ganglionic blocker, modulating autonomic nervous system activity to lower blood pressure. Over time, its use for hypertension has declined, and it is now more commonly employed as a research tool and in specialized clinical applications.
Mecamylamine is also used as an anti-addictive agent to support smoking cessation, acting on α3β4 nicotinic receptors in the brain to reduce nicotine dependence. Additionally, it has demonstrated potential in neurological conditions such as Tourette syndrome, providing relief from tics when conventional therapies have failed. Experimental studies have explored its role in psychiatric disorders, including major depressive disorder, where (S)-mecamylamine (TC-5214) was investigated as an augmentation therapy. While Phase III clinical trials did not achieve primary efficacy endpoints, the research highlighted the potential of nicotinic receptor antagonists in neuropsychiatric modulation.
Available in oral tablet form, mecamylamine hydrochloride offers a versatile pharmacological profile, combining ganglionic blockade with central nervous system effects. Its unique mechanism continues to make it valuable in clinical research and targeted therapeutic applications.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing